A Clinical Outcomes Study to Compare the Effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg With Placebo on Survival in Subjects With Moderate Chronic Obstructive Pulmonary Disease (COPD) and a History of or at Increased Risk for Cardiovascular Disease

Trial Profile

A Clinical Outcomes Study to Compare the Effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg With Placebo on Survival in Subjects With Moderate Chronic Obstructive Pulmonary Disease (COPD) and a History of or at Increased Risk for Cardiovascular Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Dec 2017

At a glance

  • Drugs Vilanterol/fluticasone furoate (Primary) ; Fluticasone furoate; Vilanterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms HZ-COPD-Mortality; SUMMIT
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Oct 2017 Results of a pre-specified analysis assessing the risk of Pneumonia with inhaled fluticasone furoate and vilanterol in chronic-obstructive-pulmonary-disease patients with moderate airflow limitation, published in the Respiratory Medicine Journal.
    • 24 Jul 2017 Results published in the American Journal of Respiratory and Critical Care Medicine.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top